Skip to main content
Figure 4 | Genetic Vaccines and Therapy

Figure 4

From: The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model

Figure 4

The presence and the therapeutic efficacy of anti-EGFR antibody in serum from the DNA vaccine group of mice. A) Anti-EGFR antibody titer in the mice serum. The serum anti-EGFR antibody in mice was determined with ELISA on dishes coated with the recombinant extracellular domain of human EGFR protein. The data represent the average titer of the sera from three mice in each group. The symbol (**) indicates a statistically significant difference when compared with the g.g non-coating DNA group mice (P < 0.05) or control mice (P < 0.001). B) B6 mice were treated with serum from control or vaccinated mice on day 5, 12, 19, 26 after s.c challenge with LL2 cells. The survival data were subjected to Kaplan-Meier analysis The symbol (*) indicates a statistically significant difference when compared with control mice group(P < 0.05). The experiments were repeated 2 times with similar results.

Back to article page

Genetic Vaccines and Therapy

ISSN: 1479-0556